1.86
price up icon14.11%   0.23
after-market After Hours: 1.92 0.06 +3.23%
loading
Curis Inc stock is traded at $1.86, with a volume of 94,408. It is up +14.11% in the last 24 hours and down -19.83% over the past month. Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$1.63
Open:
$1.65
24h Volume:
94,408
Relative Volume:
1.70
Market Cap:
$13.60M
Revenue:
$10.16M
Net Income/Loss:
$-47.57M
P/E Ratio:
-0.2257
EPS:
-8.24
Net Cash Flow:
$-42.73M
1W Performance:
+43.08%
1M Performance:
-19.83%
6M Performance:
-62.20%
1Y Performance:
-87.15%
1-Day Range:
Value
$1.65
$1.89
1-Week Range:
Value
$1.30
$1.89
52-Week Range:
Value
$1.02
$16.99

Curis Inc Stock (CRIS) Company Profile

Name
Name
Curis Inc
Name
Phone
617-503-6500
Name
Address
128 SPRING STREET, LEXINGTON, MA
Name
Employee
33
Name
Twitter
@curisinc
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
CRIS's Discussions on Twitter

Compare CRIS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CRIS
Curis Inc
1.86 13.60M 10.16M -47.57M -42.73M -8.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Curis Inc Stock (CRIS) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-17-23 Initiated Truist Buy
Apr-04-22 Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21 Initiated Raymond James Outperform
Mar-25-21 Initiated B. Riley Securities Buy
Jul-29-20 Initiated Laidlaw Buy
Jul-17-20 Initiated Cantor Fitzgerald Overweight
Oct-24-17 Initiated Guggenheim Buy
Mar-02-16 Initiated Sun Trust Rbsn Humphrey Buy
Nov-09-15 Reiterated ROTH Capital Buy
Aug-11-15 Initiated FBR Capital Outperform
Jan-22-15 Reiterated Oppenheimer Outperform
Jan-21-15 Reiterated ROTH Capital Buy
May-09-14 Reiterated Oppenheimer Outperform
Oct-02-13 Initiated Robert W. Baird Outperform
Sep-30-13 Initiated Chardan Capital Markets Buy
Nov-14-12 Initiated Stifel Nicolaus Hold
Jan-31-12 Reiterated Brean Murray Buy
Jan-31-12 Reiterated Summer Street Research Buy
Dec-09-11 Initiated Oppenheimer Outperform
Oct-06-11 Initiated Summer Street Research Buy
Sep-22-11 Initiated MLV Capital Buy
Mar-21-11 Reiterated Brean Murray Buy
Feb-26-10 Reiterated Roth Capital Buy
Jan-07-10 Initiated Roth Capital Buy
View All

Curis Inc Stock (CRIS) Latest News

pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 22, 2025

Curis (NASDAQ:CRIS) Coverage Initiated by Analysts at StockNews.com - Defense World

Apr 22, 2025
pulisher
Apr 14, 2025

Curis (NASDAQ:CRIS) Now Covered by StockNews.com - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Curis, Inc. and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration - marketscreener.com

Apr 13, 2025
pulisher
Apr 10, 2025

Form DEFA14A CURIS INC - StreetInsider

Apr 10, 2025
pulisher
Apr 10, 2025

Curis, Inc. (NASDAQ:CRIS) Q4 2024 Earnings Call Transcript - MSN

Apr 10, 2025
pulisher
Apr 09, 2025

Curis stock plunges to 52-week low at $1.1 amid sharp decline - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Curis stock plunges to 52-week low at $1.1 amid sharp decline By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Truist Removes Price Target on Curis Due to Volatility, Low Share Price; Price Target Was $26, Buy Rating Kept - marketscreener.com

Apr 09, 2025
pulisher
Apr 04, 2025

Curis targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timeline - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

HC Wainwright Forecasts Curis’ Q1 Earnings (NASDAQ:CRIS) - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Analyst Forecasts For Curis, Inc. (NASDAQ:CRIS) Are Surging Higher - Yahoo

Apr 03, 2025
pulisher
Apr 03, 2025

Curis to Present at Upcoming Healthcare Conference in April - The Malaysian Reserve

Apr 03, 2025
pulisher
Apr 03, 2025

Curis to Present at Upcoming Healthcare Conference in April 2025 - BioSpace

Apr 03, 2025
pulisher
Apr 02, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Apr 02, 2025
pulisher
Apr 02, 2025

Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS) - simplywall.st

Apr 02, 2025
pulisher
Apr 02, 2025

HC Wainwright Lowers Curis (NASDAQ:CRIS) Price Target to $16.00 - The AM Reporter

Apr 02, 2025
pulisher
Apr 01, 2025

Curis stock price target cut to $16 by H.C. Wainwright - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Curis stock plunges to 52-week low at $1.97 amid market challenges - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Curis, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates - Yahoo

Apr 01, 2025
pulisher
Apr 01, 2025

Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30% - simplywall.st

Apr 01, 2025
pulisher
Apr 01, 2025

Curis: Q4 Earnings Snapshot - CT Insider

Apr 01, 2025
pulisher
Apr 01, 2025

Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ... - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Curis (NASDAQ:CRIS) Price Target Lowered to $16.00 at HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Curis Inc. Reports Q4 2024 Progress and Financials - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Curis Inc. Earnings Call: Progress Amidst Challenges - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Curis eyes accelerated approval for cancer drug emavusertib By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Earnings call transcript: Curis Q4 2024 reveals reduced losses By Investing.com - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Curis Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Curis eyes accelerated approval for cancer drug emavusertib - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Curis Provides Fourth Quarter 2024 Business Update - PR Newswire

Mar 31, 2025
pulisher
Mar 30, 2025

Curis Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance

Mar 30, 2025
pulisher
Mar 29, 2025

Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Quantisnow

Mar 28, 2025
pulisher
Mar 28, 2025

Curis Inc Entered A Purchase Agreement To Sell 2 Million Shares Of Common Stock - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Indo-Asian News Service - Indo-Asian News Service (IANS)

Mar 28, 2025
pulisher
Mar 28, 2025

Biotech Alert: Curis Sets Date for Q4 EarningsKey Updates on IRAK4 Inhibitor Program Expected - Stock Titan

Mar 28, 2025
pulisher
Mar 25, 2025

Curis stock hits 52-week low at $2.54 amid sharp annual decline - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

Curis stock hits 52-week low at $2.54 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 24, 2025

Curis Inc Stock (CRIS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Cap:     |  Volume (24h):